GLUE240517P5000
- 0.40
- 0.000.00%
Monte Rosa Therapeutics Newsroom
Express News | Wedbush Reiterates Outperform on Monte Rosa Therapeutics, Maintains $11 Price Target
Monte Rosa Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/22/2024 150.28% Wedbush → $11 Reiterates Outperform → Outperform 02/15/2024 150.28% Wedbush → $11 Initi
Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE) and Aerovate Therapeutics (AVTE)
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits colitis disease progression and colon inflammation, lowers inflammatory mucosal cytokines, and reduces expression of IBD-associated genes in a colitis
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading
Health care stocks were mixed late Thursday afternoon, with the NYSE Health Care Index decreasing 0.1% and the Health Care Select Sector SPDR Fund (XLV) up 0.1%. The iShares Biotechnology ETF (IBB) wa
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersLucy Scientific Discovery (NASDAQ:LSDI) stock moved upwards by 123.5% to $1.14 during Thursday's pre-market session. The market value of their outstanding shares is at $2.0 million. SINTX Techs
Express News | Monte Rosa Therapeutics Shares Are Trading Lower After the Company Announced the Pricing of a $100 Million Public Offering
Express News | Monte Rosa Therapeutics - Pricing of an Underwritten Public Offering of 10.6 Mln Shares of Its Common Stock at a Public Offering Price of $4.70 /Shr
Express News | Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
Monte Rosa Therapeutics Shares Fall After Public Offering News
By Stephen Nakrosis Shares of Monte Rosa Therapeutics were trading lower in Wednesday's after-hours market, following news the company commenced an underwritten public offering of shares of common st
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersSINTX Techs (NASDAQ:SINT) shares increased by 22.2% to $0.16 during Wednesday's after-market session. The company's market cap stands at $19.1 million. As per the news, the Q1 earnings report c
Press Release: Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants BOSTON, May 15, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. ("Monte Rosa") (Nasdaq: GLUE)
Monte Rosa Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview
Buy Rating Affirmed for Monte Rosa Therapeutics Amidst Promising Drug Pipeline and Stable Financials
Express News | Monte Rosa Therapeutics Expects Its Cash And Cash Equivalents Of $197.8M To Be Sufficient To Fund Planned Operations And Capital Expenditures Into The First Half Of 2026
Express News | Monte Rosa Therapeutics Q1 2024 GAAP EPS $(0.53) Beats $(0.59) Estimate
Monte Rosa Therapeutics | 10-Q: Quarterly report
Monte Rosa Therapeutics Corporate Presentation Release
Express News | Monte Rosa Therapeutics Inc - Strong Cash Position Expected to Fund Operations Into H1 2026
Monte Rosa Therapeutics 1Q Loss/Shr 53c >GLUE
Monte Rosa Therapeutics 1Q Loss/Shr 53c >GLUE